Tazverik® (tazemetostat) voluntarily withdrawn in follicular lymphoma and epithelioid sarcoma March 17, 2026
Japan’s MHLW approves Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with 2L+ FL December 30, 2025
FDA approves EPKINLY® (epcoritamab-bysp), Rituximab and Lenalidomide combo for the Treatment of R/R Follicular Lymphoma November 24, 2025
FDA Fast Track designation for OncoMimics™ immunotherapy EO2463 in follicular lymphoma October 21, 2025
First patient with follicular lymphoma (FL) dosed in CELESTIAL-301 Ph 1 trial of SynKIR™-310 October 4, 2025
CHMP recommends EU approval of SC formulation of Lunsumio for people with R/R follicular lymphoma September 23, 2025
CIT Therapeutics Forms Strategic Partnership with IFLI, Securing Up to $2.5M to Advance Novel Cancer Therapies August 19, 2025
Ph 3 EPCORE® FL-1 Trial Met Dual Primary Endpoints in Patients with R/R Follicular Lymphoma August 12, 2025
Enterome raises $19M to fund clinical development of OncoMimics™ immunotherapy to treat Follicular Lymphoma June 24, 2025
FDA Approves Monjuvi (tafasitamab-cxix), Rituximab, and Lenalidomide Combination for Patients with R/R Follicular Lymphoma June 24, 2025
Enterome raises $19 million to fund clinical development of OncoMimics™ immunotherapy to treat Follicular Lymphoma June 17, 2025
Supplemental BLA submission to FDA for Epcoritamab + Rituximab and Lenalidomide (R2) in Patients with R/R Follicular Lymphoma planned May 6, 2025
EPKINLY® (epcoritamab) Approved by Japan MHLW for Additional Indication as a Treatment for R/R Follicular Lymphoma February 25, 2025
EU Approves TEPKINLY® (epcoritamab) for the Treatment of Adults with R/R Follicular Lymphoma August 27, 2024
Positive Topline Results from Tafasitamab (Monjuvi®) trial in R/R Follicular Lymphoma Announced August 22, 2024
NMPA accepts NDA for Tazemetostat for the Treatment of R/R Follicular Lymphoma with Priority Review Status July 9, 2024
US FDA Grants Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with R/R Follicular Lymphoma July 1, 2024
